Latest Current Report
Filed: 2026-03-12
Key Insights
- Bolt Biotherapeutics reported its Q4 2025 and full-year 2025 financial results, indicating the company's ongoing progress and development of its pipeline.
- The company did not provide any guidance or updates on key clinical programs, which may raise some uncertainty among investors about the near-term outlook.
- As an emerging growth company, Bolt Biotherapeutics has the option to take advantage of extended transition periods for complying with new or revised financial accounting standards, which could impact financial reporting and transparency.